Written by Mr Jai Seth, BSc(Hons) MBBS MRCS MSc(Urol) MD(Res) FRCS(Urol)
Consultant Urological Surgeon · Medically reviewed:
It is one of the third-line options recommended in NICE NG123 for refractory overactive bladder, alongside percutaneous tibial nerve stimulation and sacral neuromodulation. Mr Jai Seth's own published research, including a 2023 paper in Neurourology and Urodynamics on predictors of adverse events after intravesical Botox in men, and a published review of urethral sphincter Botox, informs how he selects and counsels patients.
Who is it suitable for?
- Overactive bladder symptoms (urgency, frequency, urge incontinence) that have not improved adequately with lifestyle changes, bladder retraining and a trial of antimuscarinic or beta-3 agonist medication
- Side effects from oral OAB medications that have been intolerable
- Neurogenic detrusor overactivity associated with multiple sclerosis or spinal cord injury (a separate licensed indication, with a different dose)
- Patients who can self-catheterise if temporary urinary retention occurs after the procedure (around 1 in 16 patients in the foundational RCTs)
- No active urinary tract infection at the time of the procedure
- No allergy to botulinum toxin or aminoglycoside antibiotics
How does it work?
- Botulinum toxin A blocks the release of acetylcholine at the neuromuscular junction in the bladder wall, reducing involuntary contractions of the detrusor muscle that drive urgency and urge incontinence
- Because the toxin is injected directly into the muscle and stays local, the systemic dose is small and the effect is confined to the bladder
- The effect builds over the first one to two weeks as the toxin takes hold at the nerve endings, and wears off gradually as those endings regenerate, typically over six to nine months for idiopathic OAB at the licensed 100-unit dose
- When symptoms return, the procedure can be repeated. There is no fixed limit on the number of cycles, and long-term studies show consistent response across repeat treatments
What to expect
Before the procedure
- A urine sample is checked in the days before the procedure to confirm there is no infection
- Antibiotic prophylaxis is given according to local protocol, typically a single dose around the time of the procedure
- If you take blood thinners (warfarin, apixaban, rivaroxaban, dabigatran, clopidogrel), this is reviewed in advance. Most patients can have bladder Botox while continuing anticoagulation, though specific drugs may require dose timing or omission discussed at the consultation
- A clear plan for follow-up and post-procedure self-catheterisation (if needed) is agreed before you arrive
On the day
- The procedure is usually performed under local anaesthetic (lidocaine gel) in a day-case setting; some patients prefer light sedation or a short general anaesthetic, particularly if they have had a difficult cystoscopy in the past
- A flexible or rigid cystoscope is passed gently through the urethra into the bladder
- The bladder is filled with sterile fluid so the wall can be seen clearly
- Approximately 100 units of onabotulinumtoxinA (the licensed dose for idiopathic OAB per NICE TA631) are injected through a fine needle at around 20 sites distributed across the bladder wall, sparing the trigone
- The whole procedure typically takes 15 to 20 minutes from start to finish
- You can usually go home within an hour or two of the procedure
Recovery and aftercare
- You may notice mild burning when passing urine for a day or two, this is the cystoscopy effect, not the Botox itself
- A small amount of blood in the urine is normal in the first 24 hours and clears with hydration
- You should drink plenty of fluid for the first day or two and watch for any symptoms of urinary infection
- Improvement in urgency and urge leakage typically begins within one to two weeks and reaches full effect by six weeks
- A follow-up review is arranged at around six to eight weeks to confirm response and check post-void residual urine volume
- If you experience difficulty emptying your bladder afterwards, intermittent self-catheterisation may be needed for a short period until the toxin wears off, this is discussed and taught in advance for any patient where it is a realistic possibility
Outcomes and evidence
- Phase-3 randomised controlled trials (Nitti 2013, Chapple 2013) established that 100 units of onabotulinumtoxinA significantly reduces episodes of urge urinary incontinence compared with placebo, and improves quality-of-life scores across all idiopathic OAB symptoms
- Across those foundational trials, around 60–70% of patients reported a positive treatment response at three months, and a substantial minority became fully dry from urgency leakage
- Effect duration averages six to nine months at the 100-unit dose, with repeat injections sustaining response over multiple years in long-term extension studies
- Mr Seth's own published research includes a 2023 paper in Neurourology and Urodynamics identifying clinical predictors for adverse events after intravesical Botox in men, and a review of urethral sphincter Botox applications and outcomes published in Toxins
- Mr Seth has also contributed expert commentary in Urology Times on individualised counselling for patients on blood thinners considering Botox treatments, drawing on this body of research
Risks and complications
- Urinary tract infection in the days after the procedure, managed with a short course of antibiotics
- Temporary difficulty emptying the bladder fully, which may require intermittent self-catheterisation for a few weeks until the toxin effect settles. The risk is around 1 in 16 patients at the 100-unit dose in idiopathic OAB and is one of the central topics of the consultation before the procedure
- Visible blood in the urine for the first 24 hours, which clears with fluids
- Local discomfort during or after the cystoscopy
- Allergic reaction to botulinum toxin is rare but possible, patients with a known allergy to botulinum toxin or to aminoglycoside antibiotics should not have the procedure
- Distant systemic spread of botulinum toxin is exceptionally rare at intravesical doses but is a recognised risk noted in the licensed product information
How does it compare to alternatives?
PTNS
Twelve weekly clinic sessions versus a single day-case injection. Lower risk profile, no self-catheterisation risk, but a longer time commitment and ongoing maintenance.
Sacral Neuromodulation
Implanted nerve stimulator with a test phase before permanent implant. More durable for severe refractory OAB, but involves surgery and an implant.
Mr Seth's published research
- Predictors for adverse events following intravesical botulinum toxin injections in men. Neurourology and Urodynamics (2023).
- Urethral Sphincter Injection of Botulinum Toxin A: A Review of Its Application and Outcomes. Lower Urinary Tract Symptoms (2018).
- Outcomes following percutaneous tibial nerve stimulation (PTNS) treatment for neurogenic and idiopathic overactive bladder. Clinical Autonomic Research (2020).
- Nerve growth factor (NGF): a potential urinary biomarker for overactive bladder syndrome (OAB)?. BJU International (2013).
See all publications.
Frequently asked questions
Is bladder Botox the same as cosmetic Botox?
It is the same active ingredient, botulinum toxin A, made by the same manufacturer, but used at a different site, in a different way, and at a different dose. Cosmetic Botox is injected into facial muscles in tiny amounts to relax them. Bladder Botox uses 100 units delivered into the bladder wall through a cystoscope, where it calms the involuntary contractions that drive urgency and urge incontinence. The mechanism is similar, the application is entirely separate.
How long does bladder Botox last?
On average, six to nine months at the licensed 100-unit dose for idiopathic overactive bladder. This varies between patients, some notice the effect waning at four months, others stay symptom-controlled for closer to a year. When the symptoms return, the procedure can be repeated. Long-term studies show that response is well-maintained over multiple repeat cycles.
Will I need to self-catheterise after bladder Botox?
Most patients do not. In the foundational trials at the 100-unit dose, around 1 in 16 patients with idiopathic OAB needed a period of intermittent self-catheterisation because the bladder did not empty fully after the procedure. This is the most discussed risk and is the reason every patient is taught how to self-catheterise, or has a clear plan in place, before the procedure goes ahead. If self-catheterisation is needed, it is usually for a few weeks until the Botox effect partially wears off.
Can I have bladder Botox on blood thinners?
In most cases, yes. Bladder Botox is a fine-needle injection through the bladder wall, and the bleeding risk is manageable on most anticoagulants. The specific drug, dose, indication and timing are all reviewed at the consultation. Mr Seth has co-authored research on this, including a 2023 paper on predictors for adverse events after Botox in men and published commentary in Urology Times on individualised counselling for patients on blood thinners, so patients on warfarin, apixaban, rivaroxaban, dabigatran or clopidogrel can be counselled with reference to current evidence rather than blanket caution.
Is it painful?
Most patients describe it as uncomfortable rather than painful. The local anaesthetic gel is applied generously and given time to work. The injections themselves are felt as small pinpricks. Some patients prefer light sedation or a short general anaesthetic, particularly if they have had a difficult cystoscopy before, this is a personal choice discussed at the consultation.
How quickly will I notice an improvement?
Most patients notice a difference in urgency and leakage within one to two weeks. The full effect typically takes six weeks to develop as the toxin spreads through the bladder wall and reaches all the targeted nerve endings. A six-to-eight week follow-up appointment is arranged to confirm response.
What happens when the Botox wears off?
Symptoms gradually return as the nerve endings regenerate. There is rarely a sudden rebound, most patients notice urgency and frequency creeping back over a few weeks. At that point, the procedure can be repeated. There is no fixed limit on the number of cycles, and the procedure does not become less effective with repeat use in the long-term studies.
Is bladder Botox available on the NHS or only privately?
Both. Bladder Botox at the 100-unit dose for idiopathic OAB is recommended by NICE and is available on the NHS for patients who meet the criteria. Private treatment offers shorter waiting times and continuity with the same consultant from initial consultation through to follow-up. Mr Seth treats patients privately at Nuffield Health Parkside Hospital and his other consulting locations.
Are there alternatives to bladder Botox?
Yes. The other third-line options for OAB that has not responded to lifestyle and medication are percutaneous tibial nerve stimulation (PTNS) and sacral neuromodulation. PTNS uses a fine needle near the ankle to deliver weekly nerve-stimulation sessions over twelve weeks, with monthly maintenance after. Sacral neuromodulation involves an implanted nerve stimulator and is offered in two stages, with a test phase before permanent implantation. The right choice depends on patient preference, anatomy, and which side effects matter most. The decision is a conversation, not a default.
Book a consultation with Mr Jai Seth
Private appointments available at Nuffield Health Parkside Hospital, Wimbledon, and other consulting locations across London.
Book an appointment